Xenon Pharmaceuticals Inc.

NasdaqGM:XENE 주식 보고서

시가총액: US$2.9b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Xenon Pharmaceuticals 미래 성장

Future 기준 확인 2/6

Xenon Pharmaceuticals (는) 각각 연간 18.6% 및 73.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -56.8% 로 예상됩니다.

주요 정보

19.1%

수익 성장률

22.3%

EPS 성장률

Biotechs 수익 성장28.5%
매출 성장률74.1%
향후 자기자본 수익률-56.8%
애널리스트 커버리지

Good

마지막 업데이트10 Sep 2024

최근 미래 성장 업데이트

Recent updates

Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain

Aug 09

Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?

Aug 09
Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?

Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans

Jul 05
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans

We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right

May 29
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right

Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Apr 16
Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Mar 12
Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'

Feb 08

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Oct 21
Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Jun 22
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Feb 15
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Oct 27
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Xenon started at outperform at Raymond James on experimental epilepsy drug

Oct 19

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Sep 22
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Putting Xenon Pharmaceuticals Back In The Spotlight

Sep 06

Xenon initiated with Buy at BofA citing potential of anti-seizure drug

Aug 29

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Jun 13
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Sizing Up Xenon Pharmaceuticals

Dec 13

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Nov 12
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Aug 05
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%

May 13
Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Apr 14
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?

Mar 16
Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?

수익 및 매출 성장 예측

NasdaqGM:XENE - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202647-337-283-29111
12/31/20256-289-240-26414
12/31/20240-241-207-20414
6/30/2024N/A-199-157-154N/A
3/31/2024N/A-189-158-154N/A
12/31/2023N/A-182-151-145N/A
9/30/2023N/A-175-150-143N/A
6/30/20230-165-137-131N/A
3/31/20231-148-119-114N/A
12/31/20229-126-101-98N/A
9/30/202213-113-88-86N/A
6/30/202221-91-73-71N/A
3/31/202223-83-69-67N/A
12/31/202118-81-72-70N/A
9/30/202120-66-64-62N/A
6/30/202118-59-61-58N/A
3/31/202129-37-58-56N/A
12/31/202032-29-51-48N/A
9/30/202030-28-18-15N/A
6/30/202027-28-13-11N/A
3/31/202014-38-11-9N/A
12/31/20197-42-6-5N/A
9/30/20194-39-33-32N/A
6/30/2019N/A-44-39-38N/A
3/31/2019N/A-42-36-35N/A
12/31/2018N/A-34-35-35N/A
9/30/20180-34-35-34N/A
6/30/20180-27-30-29N/A
3/31/20180-27N/A-30N/A
12/31/20170-31N/A-29N/A
9/30/20171-29N/A-27N/A
6/30/20171-29N/A-22N/A
3/31/20171-27N/A-21N/A
12/31/20162-23N/A-20N/A
9/30/20165-21N/A-20N/A
6/30/20169-17N/A-21N/A
3/31/201612-10N/A-17N/A
12/31/201516-16N/A-18N/A
9/30/201517-2N/A-16N/A
6/30/2015265N/A-5N/A
3/31/2015274N/A-4N/A
12/31/20142813N/A0N/A
9/30/2014296N/A1N/A
6/30/2014274N/A-1N/A
3/31/2014274N/A-1N/A
12/31/2013274N/A-3N/A

애널리스트 미래 성장 예측

수입 대 저축률: XENE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: XENE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: XENE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: XENE 의 수익(연간 73.5% ) US 시장( 8.8% 보다 빠르게 성장할 것으로 예상됩니다. 8.8% 연간).

고성장 수익: XENE 의 수익(연간 73.5% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: XENE (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견